Spirax Group (SPX) Report Interpretation

Overview

This earnings review assesses Spirax Group’s H1 performance and the outlook for its STS, ETS and Watson-Marlow businesses. Deutsche Bank sees the results as solid overall and believes the initial share-price reaction was excessive, but retains Hold because the market remains focused on the pace and credibility of an STS recovery relative to the valuation multiple.

Core views

Deutsche Bank describes the results as solid overall. Although Spirax shares had risen strongly into the announcement and initially fell 11%, the report considers that reaction overdone. H1 EBIT was €171m, about 4% ahead of Deutsche Bank’s expectation, while EPS was about 6% ahead. The institution expects the share price to recover as attention moves beyond the headline STS organic-growth miss of 1% versus its 2% estimate, which it says implies a softer second quarter, to more positive management commentary on the results call. The central debate remains Spirax Thermal Solutions (STS). STS organic growth was down 6%, as investment timing and deliveries of large projects were less favourable year on year. Management indicated that large-project shipments reduced H1 organic growth by about 1 percentage point, equivalent to only a couple of trading days, and said current activity is now growing at more than 3% year on year, with a modest increase in large-project orders. Deutsche Bank expects STS growth to improve in H2 because of the opening order book and continuing order momentum. The group’s 45%:55% H1:H2 EBIT guidance implies about £205m of full-year EBIT, compared with Deutsche Bank’s estimate of roughly £200m. The report expects a marginal increase in FY26 consensus EBIT, with a better foreign-exchange outlook partly offset by higher central costs. For the medium-term STS outlook, management kept its view that China should return to growth in late 2026 or early 2027. China was down 1% year on year in H1, an improvement from a 6% decline in H1 2025. From current industrial-production growth of about 1.5%, management outlined a path to 3–4% growth plus a further 1 percentage point from decarbonisation and digital tailwinds. Deutsche Bank assumes 3% OCC sales growth in FY27 and notes that FY26 guidance could be met even without an H2 improvement in industrial production. Engineering Technology Solutions (ETS) was the strongest operational feature. Organic growth was 11%, ahead of Deutsche Bank’s 9% estimate, marking a third consecutive period of at least 10% growth. Semiconductor demand led the growth, and the business achieved a 220bp year-on-year organic margin improvement; it reached a 20% EBIT margin for one month during H1. Deutsche Bank remains confident in its 20% ETS margin forecast for FY27E. ETS generated 27% year-on-year organic profit growth. Watson-Marlow grew organically by 7%, slightly below Deutsche Bank’s 8% estimate, but the report highlights encouraging underlying indicators: Q2 order intake was the highest since 2021 and margins improved. Watson-Marlow generated 11% year-on-year organic profit growth. Together, the stronger ETS and Watson-Marlow performance contrasts with weak STS growth and supports Deutsche Bank’s view that the reported STS shortfall should not dominate the overall assessment.

Analysis framework

Deutsche Bank compares reported H1 EBIT, EPS and segment organic growth with its own estimates, then separates the performance of STS, ETS and Watson-Marlow. It uses management commentary on order books, project timing, industrial-production growth, China, margins and guidance to assess the expected H2 and FY27 trajectory.

Methodology notes

• Industry AnalysisSupply-demand framework

  Order-book, project-delivery and industrial-activity analysis

  The report uses starting order books, new large-project orders, investment timing and industrial-production growth to explain STS’s H1 weakness and its expected H2 recovery.

• Industry AnalysisVolume-price decomposition

  Organic growth and margin analysis by business segment

  The report evaluates ETS and Watson-Marlow through organic revenue growth, order intake, EBIT margins and organic profit growth, separating operational performance by segment.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Spirax Group (SPX.L)

  Primary covered company; H1 earnings beat expectations, with stronger ETS and Watson-Marlow execution offsetting weaker STS growth.

  Strengths

  H1 EBIT and EPS beat Deutsche Bank expectations; ETS delivered 11% organic growth, margin expansion and semiconductor-led demand; Watson-Marlow order intake and margins were encouraging.

  Weaknesses

  STS growth was weak because of unfavourable investment timing and large-project deliveries; Watson-Marlow growth was slightly below expectation.

  Comparison

  ETS organic growth of 11% exceeded Deutsche Bank’s 9% expectation, while Watson-Marlow’s 7% was just below its 8% expectation and STS’s 1% was below its 2% expectation.

  Risks

  The report highlights the ongoing debate over STS organic-growth recovery versus the valuation multiple paid.

Key data

• H1 EBIT€171mApproximately 4% above Deutsche Bank expectations.
• H1 EPS—Approximately 6% above Deutsche Bank expectations; no absolute EPS value was stated.
• STS organic growth1%Versus Deutsche Bank expectation of 2%; STS was down 6% on the segment comparison cited in the report.
• ETS organic growth+11%Versus Deutsche Bank expectation of +9%; third successive period of at least 10% organic growth.
• ETS organic margin change+220bp year on yearThe business reached a 20% EBIT margin for one month in H1.
• Watson-Marlow organic growth+7%Slightly below Deutsche Bank expectation of +8%; Q2 order intake was the highest since 2021.
• FY26 implied EBITc.£205mImplied by 45%:55% H1:H2 EBIT guidance, versus Deutsche Bank estimate of c.£200m.
• FY27 ETS EBIT margin forecast20%Deutsche Bank remains confident in this estimate.
• FY27 OCC sales growth assumption3%Deutsche Bank assumption for the STS outlook.

Impact & implications

The report argues that better-than-expected group earnings and strong ETS execution reduce the significance of the STS headline miss. However, the investment debate remains tied to evidence that STS can progress from current activity levels to the medium-term growth outlook, particularly given the valuation multiple paid for the business.

What to watch

• Evidence of an H2 STS growth improvement from the starting order book and ongoing order momentum.
• Large-project order trends and the impact of project shipments on STS organic growth.
• The timing of China’s return to growth, which management still expects in late 2026 or early 2027.
• ETS margin progression toward Deutsche Bank’s 20% FY27E forecast.
• Whether foreign-exchange benefits and higher central costs result in a marginal increase in FY26 consensus EBIT.